Acupuncture for the Treatment of Medication-Dependent Hypotension in Heart Failure
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Yu-Ming Ni, MD
- Phone Number: 858-554-3360
- Email: acupunctureHF@scrippshealth.org
Study Contact Backup
- Name: Christopher Suhar, MD
- Phone Number: 858-554-3300
Study Locations
-
-
California
-
La Jolla, California, United States, 92037
- Recruiting
- Scripps La Jolla Medical Center
-
Contact:
- Yu-Ming Ni, MD
- Phone Number: 858-554-3360
- Email: acupunctureHF@scrippshealth.org
-
Contact:
- Christopher Suhar, MD
- Phone Number: 858-554-3300
-
Sub-Investigator:
- Yu-Ming Ni, MD
-
La Jolla, California, United States, 92037
- Recruiting
- Scripps Shiley Integrative Center
-
Contact:
- Yu-Ming Ni, MD
- Phone Number: 858-554-3360
- Email: acupunctureHF@scrippshealth.org
-
Contact:
- Christopher Suhar, MD
- Phone Number: 858-554-3300
-
Sub-Investigator:
- Yu-Ming Ni, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age greater than or equal to 18 years old
- Chronic congestive heart failure (systolic or diastolic)
- Medication list includes midodrine or fludrocortisone, either taking as scheduled or as needed
Exclusion Criteria:
- History of acupuncture of any kind in the last 3 months
- Acute decompensated heart failure, as indicated by clinical picture at time of enrollment
- Currently on a mechanical device (LVAD, TAH, ECMO)
- History of hepatorenal syndrome, adrenal insufficiency, for which midodrine and fludrocortisone respectively is specifically being used to treat that condition
- Lack of suitable locations for which to place acupuncture seeds
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: True Acupuncture
|
Delivery of four acupuncture seeds (no needles involved) to the head and neck area at true acupuncture points.
|
|
SHAM_COMPARATOR: Sham Acupuncture
|
Delivery of four acupuncture seeds (no needles involved) to the head and neck area at non-acupuncture points.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood Pressure
Time Frame: 9 weeks
|
Change in mean arterial blood pressure, as measured by blood pressure cuff in sitting position
|
9 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood Pressure adjusted for Medication
Time Frame: 9 weeks
|
Change in mean arterial blood pressure, as measured by blood pressure cuff in sitting position, adjusted for midodrine/fludrocortisone dose as covariate
|
9 weeks
|
|
Standing Blood Pressure adjusted for Medication
Time Frame: 9 weeks
|
Change in mean arterial blood pressure, as measured by blood pressure cuff in standing position, adjusted for midodrine/fludrocortisone dose as covariate
|
9 weeks
|
|
Medication Dose Change
Time Frame: 9 weeks
|
Percentage change in median dose of midodrine or fludrocortisone (in mg per week)
|
9 weeks
|
|
Got off medications
Time Frame: 9 weeks
|
Number of patients who came off of midodrine or fludrocortisone by end of study
|
9 weeks
|
|
NYHA Class
Time Frame: Start, 5 weeks, and 9 weeks
|
Change in NYHA Class
|
Start, 5 weeks, and 9 weeks
|
|
Quality of Life Score
Time Frame: Start, 5 weeks, and 9 weeks
|
Change in Quality of Life scores by VAS
|
Start, 5 weeks, and 9 weeks
|
|
Composite Safety Outcome
Time Frame: Throughout study, total time 9 weeks
|
Composite of skin injury, symptomatic hypotension, hospitalization for heart failure exacerbation or syncope or hypotension, implantation of LVAD/MCS device or heart transplantation, or all-cause death
|
Throughout study, total time 9 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Christopher Suhar, MD, Scripps Health
- Principal Investigator: Yu-Ming Ni, MD, Scripps Health
- Principal Investigator: Rajeev Mohan, MD, Scripps Health
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB-20-7569
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.